OncoMatch/Clinical Trials/NCT06801041

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

Is NCT06801041 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Psilocybin for depression.

Phase 2RecruitingM.D. Anderson Cancer CenterNCT06801041Data as of Jun 2026

Treatment: Psilocybin — This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Psilocybin

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

The University of Texas M. D. Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06801041 currently recruiting?

Yes, this trial is currently recruiting patients.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify